Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119686 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
A Phase 2 study, sponsored by Arthrosi Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT05119686 is a Phase 2 study that has completed, run by Arthrosi Therapeutics. The registered enrollment target is 140 participants.
The verdict
NCT05119686, a Phase 2 study, has completed, sponsored by Arthrosi Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.
Interventions
- DRUG Placebo
- DRUG AR882 Dose 1
- DRUG AR882 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05119686
The ClinicalTrials.gov registry entry for NCT05119686 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arthrosi Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05119686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05119686 about?
NCT05119686 is a clinical study titled "Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients". This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.
What is the current status of trial NCT05119686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2021-11-16. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT05119686?
The interventions under investigation include: Placebo (DRUG), AR882 Dose 1 (DRUG), AR882 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT05119686?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.